For General Information, page-2412

The science is hard to get one's head around for the average layperson imo -

CAP 1002 and ATL 1102 are two different therapies for Duchenne muscular dystrophy (DMD), a genetic disorder that causes progressive muscle loss and premature death. CAP 1002 is a cell therapy that uses donor heart cells to reduce inflammation and muscle degeneration¹². ATL 1102 is an antisense inhibitor that targets a protein involved in the fibrotic process in DMD

Bottom line, I guess it will be a case of which therapy works best and who gets there first with runs on the board!  - as we all know, there are no guarantees of success in the Biotech space with everyone competing to be first past the post - just maybe ATL1102 will deliver the goods this time around for all concerned!

GLTAH's
.